AlphAIAlphAI — Financial news for AI agents
tradingview.com$ACRV

Acrivon Therapeutics, Inc. (ACRV) Advances Oral CDK11 Drug Toward H1 2027 IND

Acrivon Therapeutics (ACRV) announced progress in its oral CDK11 inhibitor, ACR-7280, advancing it to IND-enabling studies. The company aims to file an IND in the first half of 2027, with an initial focus on acute myeloid leukemia (AML) after demonstrating complete tumor regression in xenograft models.

Original reporting
tradingview.com
Published Oct 20, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 12:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Acrivon Therapeutics, Inc. (ACRV) Advances Oral CDK11 Drug Toward H1 2027 IND — source image
Source · tradingview.com
Decision brief

The 30-second read

$ACRVBullishLow
01

Why it matters

The IND‑enabling update provides a concrete milestone that could improve investor sentiment, but the timeline extends several years.

02

Market read

First public disclosure of a new IND‑enabling program; modest but material for the stock.

03

What to watch

Potential regulatory hurdles and competition from other AML therapies could dampen the catalyst.

Relevance 7/10Novelty 8/10Timing: mid‑2027 IND filing window

Background

Acrivon Therapeutics (NASDAQ: ACRV) is a clinical‑stage biotech developing CDK11 inhibitors for cancer.

Company-level read

Ticker impact

$ACRVBullishMedium confidence
Context

ACRV announced advancement of its oral CDK11 inhibitor ACR-7280 into IND-enabling studies and plans an IND filing in H1 2027, focusing on AML.

Expected impact

potential upside as market prices in the upcoming IND filing and early AML data

Evidence & confidence

First disclosure of a new IND-enabling program for a micro‑cap biotech; no prior public detail, so the news is material but the catalyst is years away.

Market effects

Sector

May spark modest interest in the broader CDK inhibitor and AML therapeutic space.

Regional

Limited to U.S. biotech investors; no immediate regional effect.

Global

Low global impact; primarily relevant to niche biotech investors.

Counterpoint

What could challenge this read

The long lead time to IND filing and early‑stage data could mean the news is already priced in, limiting upside.

Key entities

  • company
    Acrivon Therapeutics, Inc.

    Biotech firm advancing oral CDK11 inhibitor ACR-7280.

Read at source← All news

StoryAcrivon moves oral CDK11 inhibitor toward IND filing in early 2027

Related articles

$ACRVMedAI 8/10

Acrivon Therapeutics Highlights Phase 2-Ready ACR-525 and Preclinical EoE Programs

Acrivon Therapeutics presented its immunology and inflammation programs, including the Phase 2-ready ACR-525, a selective JAK1 inhibitor, and a preclinical PKCθ inhibitor program, at an R&D event. The company highlighted EoE's growing patient population and treatment gaps as rationale for ACR-525's development, citing favorable early clinical data and safety profile. The presentation is available on the company's investor website.

tradingview.com
$ACRVMedAI 8/10

Acrivon to present cancer drug trial data at November symposium

Acrivon Therapeutics (ACRV) will present Phase 1/2 trial data for ACR-2316 at a cancer symposium in November. The study showed clinical activity in endometrial and lung cancers, with one patient achieving complete response. The trial has progressed to dose expansion, including pancreatic cancer patients. ACRV uses its AP3 platform to predict patient responses.

investing.com
$ACRVMedAI 8/10

Acrivon advances CDK11 inhibitor for AML, targets 2027 IND filing

Acrivon Therapeutics (ACRV) announced the advancement of ACR-7280, an oral CDK11 inhibitor, as its next development candidate. The company plans to file an IND application for the drug with the FDA in the first half of 2027. ACR-7280 showed complete tumor regression in AML xenograft models and potential in combination therapies. Acrivon's lead program, ACR-368, is in a Phase 2 trial for endometrial cancer.

investing.com
$ACRVMed

Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

Acrivon Therapeutics, Inc. (ACRV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026 ACR-2316 P

SEC EDGAR 8-K
$ASTSMedAI 8/10

Rakuten, AST SpaceMobile Establish JV for Japan Satellite Communications Network

Rakuten Group and AST SpaceMobile formed a joint venture, Rakuten AST, to build a satellite communications network in Japan. The project, supported by up to 148 billion yen in funding, aims to provide direct-to-device connectivity for smartphones, enhancing disaster resilience. Rakuten AST plans to commence operations by March 2029, leveraging AST SpaceMobile's satellites for high-speed internet access.

thefastmode.com